Cargando…

Alpha-enolase in viral target cells suppresses the human immunodeficiency virus type 1 integration

BACKGROUND: A protein exhibiting more than one biochemical function is termed a moonlighting protein. Glycolytic enzymes are typical moonlighting proteins, and these enzymes control the infection of various viruses. Previously, we reported that glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and al...

Descripción completa

Detalles Bibliográficos
Autores principales: Kishimoto, Naoki, Yamamoto, Kengo, Iga, Nozomi, Kirihara, Chie, Abe, Towa, Takamune, Nobutoki, Misumi, Shogo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488571/
https://www.ncbi.nlm.nih.gov/pubmed/32917235
http://dx.doi.org/10.1186/s12977-020-00539-9
_version_ 1783581719549444096
author Kishimoto, Naoki
Yamamoto, Kengo
Iga, Nozomi
Kirihara, Chie
Abe, Towa
Takamune, Nobutoki
Misumi, Shogo
author_facet Kishimoto, Naoki
Yamamoto, Kengo
Iga, Nozomi
Kirihara, Chie
Abe, Towa
Takamune, Nobutoki
Misumi, Shogo
author_sort Kishimoto, Naoki
collection PubMed
description BACKGROUND: A protein exhibiting more than one biochemical function is termed a moonlighting protein. Glycolytic enzymes are typical moonlighting proteins, and these enzymes control the infection of various viruses. Previously, we reported that glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and alpha-enolase (ENO1) are incorporated into human immunodeficiency virus type 1 (HIV-1) particles from viral producer cells and suppress viral reverse transcription independently each other. However, it remains unclear whether these proteins expressed in viral target cells affect the early phase of HIV-1 replication. RESULTS: Here we show that the GAPDH expression level in viral target cells does not affect the early phase of HIV-1 replication, but ENO1 has a capacity to suppress viral integration in viral target cells. In contrast to GAPDH, suppression of ENO1 expression by RNA interference in the target cells increased viral infectivity, but had no effect on the expression levels of the HIV-1 receptors CD4, CCR5 and CXCR4 and on the level of HIV-1 entry. Quantitative analysis of HIV-1 reverse transcription products showed that the number of copies of the late products (R/gag) and two-long-terminal-repeat circular forms of viral cDNAs did not change but that of the integrated (Alu-gag) form increased. In contrast, overexpression of ENO1 in viral target cells decreased viral infectivity owing to the low viral integration efficiency. Results of subcellular fractionation experiments suggest that the HIV integration at the nucleus was negatively regulated by ENO1 localized in the nucleus. In addition, the overexpression of ENO1 in both viral producer cells and target cells most markedly suppressed the viral replication. CONCLUSIONS: These results indicate that ENO1 in the viral target cells prevents HIV-1 integration. Importantly, ENO1, but not GAPDH, has the bifunctional inhibitory activity against HIV-1 replication. The results provide and new insights into the function of ENO1 as a moonlighting protein in HIV-1 infection.
format Online
Article
Text
id pubmed-7488571
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74885712020-09-16 Alpha-enolase in viral target cells suppresses the human immunodeficiency virus type 1 integration Kishimoto, Naoki Yamamoto, Kengo Iga, Nozomi Kirihara, Chie Abe, Towa Takamune, Nobutoki Misumi, Shogo Retrovirology Research BACKGROUND: A protein exhibiting more than one biochemical function is termed a moonlighting protein. Glycolytic enzymes are typical moonlighting proteins, and these enzymes control the infection of various viruses. Previously, we reported that glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and alpha-enolase (ENO1) are incorporated into human immunodeficiency virus type 1 (HIV-1) particles from viral producer cells and suppress viral reverse transcription independently each other. However, it remains unclear whether these proteins expressed in viral target cells affect the early phase of HIV-1 replication. RESULTS: Here we show that the GAPDH expression level in viral target cells does not affect the early phase of HIV-1 replication, but ENO1 has a capacity to suppress viral integration in viral target cells. In contrast to GAPDH, suppression of ENO1 expression by RNA interference in the target cells increased viral infectivity, but had no effect on the expression levels of the HIV-1 receptors CD4, CCR5 and CXCR4 and on the level of HIV-1 entry. Quantitative analysis of HIV-1 reverse transcription products showed that the number of copies of the late products (R/gag) and two-long-terminal-repeat circular forms of viral cDNAs did not change but that of the integrated (Alu-gag) form increased. In contrast, overexpression of ENO1 in viral target cells decreased viral infectivity owing to the low viral integration efficiency. Results of subcellular fractionation experiments suggest that the HIV integration at the nucleus was negatively regulated by ENO1 localized in the nucleus. In addition, the overexpression of ENO1 in both viral producer cells and target cells most markedly suppressed the viral replication. CONCLUSIONS: These results indicate that ENO1 in the viral target cells prevents HIV-1 integration. Importantly, ENO1, but not GAPDH, has the bifunctional inhibitory activity against HIV-1 replication. The results provide and new insights into the function of ENO1 as a moonlighting protein in HIV-1 infection. BioMed Central 2020-09-11 /pmc/articles/PMC7488571/ /pubmed/32917235 http://dx.doi.org/10.1186/s12977-020-00539-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kishimoto, Naoki
Yamamoto, Kengo
Iga, Nozomi
Kirihara, Chie
Abe, Towa
Takamune, Nobutoki
Misumi, Shogo
Alpha-enolase in viral target cells suppresses the human immunodeficiency virus type 1 integration
title Alpha-enolase in viral target cells suppresses the human immunodeficiency virus type 1 integration
title_full Alpha-enolase in viral target cells suppresses the human immunodeficiency virus type 1 integration
title_fullStr Alpha-enolase in viral target cells suppresses the human immunodeficiency virus type 1 integration
title_full_unstemmed Alpha-enolase in viral target cells suppresses the human immunodeficiency virus type 1 integration
title_short Alpha-enolase in viral target cells suppresses the human immunodeficiency virus type 1 integration
title_sort alpha-enolase in viral target cells suppresses the human immunodeficiency virus type 1 integration
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488571/
https://www.ncbi.nlm.nih.gov/pubmed/32917235
http://dx.doi.org/10.1186/s12977-020-00539-9
work_keys_str_mv AT kishimotonaoki alphaenolaseinviraltargetcellssuppressesthehumanimmunodeficiencyvirustype1integration
AT yamamotokengo alphaenolaseinviraltargetcellssuppressesthehumanimmunodeficiencyvirustype1integration
AT iganozomi alphaenolaseinviraltargetcellssuppressesthehumanimmunodeficiencyvirustype1integration
AT kiriharachie alphaenolaseinviraltargetcellssuppressesthehumanimmunodeficiencyvirustype1integration
AT abetowa alphaenolaseinviraltargetcellssuppressesthehumanimmunodeficiencyvirustype1integration
AT takamunenobutoki alphaenolaseinviraltargetcellssuppressesthehumanimmunodeficiencyvirustype1integration
AT misumishogo alphaenolaseinviraltargetcellssuppressesthehumanimmunodeficiencyvirustype1integration